TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

How does BiTE® AMG 701 compare to other immunotherapies for heavily pretreated patients?

Featured:

Suzanne LentzschSuzanne Lentzsch

Jan 29, 2021


Video series

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Suzanne Lentzsch, Columbia University, New York, US. We asked, How does the bispecific T-cell engager (BiTE®) AMG 701 compare to other immunotherapies for heavily pretreated patients?

In this video, Lentzsch discusses the first-in-human clinical trial assessing AMG 701, an anti-B-cell maturation antigen BiTE® molecule, in a heavily pretreated relapsed/refractory patient population. She then compares AMG 701 with other immunotherapies and comments that it is too early to give a final verdict on the best antibody.